Saturday, July 11, 2026

Drug profile · INN

pitavastatin magnesium

pitavastatin magnesium (ZYPITAMAG) is a hmg-coa reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — pitavastatin magnesium
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

pitavastatin magnesium (ZYPITAMAG) is a hmg-coa reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN pitavastatin magnesium
Brand ZYPITAMAG
Mechanism HMG-CoA reductase inhibitor
Target 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Route ORAL
Formulation TABLET

Mechanism of action

HMG-CoA reductase inhibitor

Primary target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. atorvastatin calcium HMG-CoA reductase inhibitor
  2. fluvastatin sodium HMG-CoA reductase inhibitor
  3. lovastatin HMG-CoA reductase inhibitor
  4. pitavastatin calcium HMG-CoA reductase inhibitor
  5. rosuvastatin calcium HMG-CoA reductase inhibitor
  6. simvastatin HMG-CoA reductase inhibitor

Frequently asked questions

What is pitavastatin magnesium?

pitavastatin magnesium (ZYPITAMAG) is a hmg-coa reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for pitavastatin magnesium?

ZYPITAMAG is a marketed brand name for pitavastatin magnesium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pitavastatin magnesium?

pitavastatin magnesium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.